dc.contributor.author |
Nunthanavanit P. |
|
dc.contributor.author |
Anthony N.G. |
|
dc.contributor.author |
Johnston B.F. |
|
dc.contributor.author |
Mackay S.P. |
|
dc.contributor.author |
Ungwitayatorn J. |
|
dc.date.accessioned |
2021-04-05T04:31:58Z |
|
dc.date.available |
2021-04-05T04:31:58Z |
|
dc.date.issued |
2008 |
|
dc.identifier.issn |
3656233 |
|
dc.identifier.other |
2-s2.0-50949092681 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/14850 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-50949092681&doi=10.1002%2fardp.200700229&partnerID=40&md5=2a49c59d1f6f111004e25d0b3640205e |
|
dc.description.abstract |
Three-dimensional quantitative structure-activity relationship (3D-QSAR) models were developed for chromone derivatives against HIV-1 protease using molecular field analysis (MFA) with genetic partial least square algorithms (G/PLS). Three different alignment methods: field fit, pharmacophore-based, and receptor-based were used to derive three MFA models. All models produced good predictive ability with high cross-validated r2 (r2 cv), conventional r2, and predictive r2 (r 2pred) values. The receptor-based MFA showed the best statistical results with r2cv = 0.789, r2 = 0.886, and r2pred = 0.995. The result obtained from the receptor-based model was compared with the docking simulation of the most active compound 21 in this chromone series to the binding pocket of HIV-1 protease (PDB entry 1AJX). It was shown that the MFA model related well with the binding structure of the complex and can provide guidelines to design more potent HIV-1 protease inhibitors. © 2008 Wiley-VCH Verlag GmbH & Co. KGaA. |
|
dc.subject |
chromone derivative |
|
dc.subject |
proteinase inhibitor |
|
dc.subject |
chromone derivative |
|
dc.subject |
p16 protease, Human immunodeficiency virus 1 |
|
dc.subject |
proteinase |
|
dc.subject |
proteinase inhibitor |
|
dc.subject |
article |
|
dc.subject |
drug protein binding |
|
dc.subject |
molecular model |
|
dc.subject |
pharmacophore |
|
dc.subject |
predictive validity |
|
dc.subject |
priority journal |
|
dc.subject |
quantitative structure activity relation |
|
dc.subject |
simulation |
|
dc.subject |
three dimensional imaging |
|
dc.subject |
algorithm |
|
dc.subject |
binding site |
|
dc.subject |
chemical structure |
|
dc.subject |
chemistry |
|
dc.subject |
conformation |
|
dc.subject |
drug design |
|
dc.subject |
regression analysis |
|
dc.subject |
Algorithms |
|
dc.subject |
Binding Sites |
|
dc.subject |
Chromones |
|
dc.subject |
Drug Design |
|
dc.subject |
HIV Protease |
|
dc.subject |
HIV Protease Inhibitors |
|
dc.subject |
Least-Squares Analysis |
|
dc.subject |
Models, Molecular |
|
dc.subject |
Molecular Conformation |
|
dc.subject |
Quantitative Structure-Activity Relationship |
|
dc.title |
3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: Application of molecular field analysis |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Archiv der Pharmazie. Vol 341, No.6 (2008), p.357-364 |
|
dc.identifier.doi |
10.1002/ardp.200700229 |
|